Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal ABCWY vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal ABCWY vaccine (specifically the candidate developed by GSK, often identified as GSK3536852A) is a pentavalent combination vaccine designed to provide broad protection against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. It is formulated by combining the components of two existing GSK vaccines: Bexsero (a multicomponent serogroup B vaccine) and Menveo (a quadrivalent A, C, W-135, and Y conjugate vaccine). The vaccine aims to simplify immunization schedules by covering the five most prevalent serogroups in a single product, particularly for adolescents and infants. It utilizes a combination of recombinant proteins, outer membrane vesicles (OMV), and polysaccharide-protein conjugates to elicit a robust bactericidal antibody response against the targeted serogroups.
- Brand names
- Penbraya
- Other names
- combined meningococcal ABCWY vaccinepentavalent meningococcal vaccineGSK MenABCWY
02
Targets
fHbp (Factor H-binding protein)NadA (Neisserial adhesin A)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)NHBA (Neisserial heparin-binding antigen)MenB OMV (Neisseria meningitidis serogroup B outer membrane vesicle)
Beyond the preview
Go deeper on meningococcal ABCWY vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal ABCWY vaccine.